UNSPSC 51102848: Fluorometholone/sulfacetamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51102848 Fluorometholone/sulfacetamide is a Commodity code that nominally denotes a specific ophthalmic pharmaceutical product, but recent state and local solicitations tagged with this code show little alignment with that scope. The most recent opportunities under the code involve emergency medical supplies, pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription programs — none of which match the narrow pharmaceutical scope of the code name. Issuing bodies include county health departments (Seminole County, Florida), city fire departments (Tampa Fire Department Rescue Division), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The mismatch between the code designation and actual procurement activity suggests either tagging errors in the source data or mission drift in how the code is being applied at the state and local level.

Geographic activity spans Florida, Texas, Minnesota, and Oregon through cooperative purchasing participation. Representative recent opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023; the City of Tampa's IFB 26P00145, posted March 25, 2026, for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a response deadline of March 13, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The code shows active procurement activity but the products being solicited do not consistently reflect the code's nominal pharmaceutical classification.